<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":2487,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Lofton v. McNeil Consumer & Specialty Pharmaceuticals, 672 F.3d 372 (5th Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/300f61bc5669c9545c40658d67baf057'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/300f61bc5669c9545c40658d67baf057'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation distinguished" title="Distinguished"></div>
<div class='title left' title='Lofton v. McNeil Consumer &amp; Specialty Pharmaceuticals, 672 F.3d 372 (5th Cir. 2012), Court Opinion'>
Lofton v. McNeil Consumer &amp; Specialty Pharmaceuticals, 672 F.3d 372 (5th Cir. 2012), Court...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Lofton v. McNeil Consumer & Specialty Pharmaceuticals, 672 F.3d 372 (5th Cir. 2012), Court Opinion</div>
<div class='docId'>X1H5V5A003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Lofton v. McNeil Consumer & Specialty Pharmaceuticals</div>
<div class='displayCitation'>2012 BL 42535</div>
<div class='displayCitation'>672 F.3d 372</div>
<div class='displayCitation'>bna a0d0w8k1c1</div>
<div class='displayCitation'>wkf5case:25787989</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1H5V5A003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Lofton v. McNeil Consumer &amp; Specialty Pharmaceuticals, 672 F.3d 372 (5th Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Lofton v. McNeil Consumer &amp; Specialty Pharmaceuticals" />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1H5V5A003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1H5V5A003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1H5V5A003" /><input id="title" name="title" type="hidden" value="Lofton v. McNeil Consumer &amp; Specialty Pharmaceuticals, 672 F.3d 372 (5th Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="DISTINGUISHED" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="300f61bc5669c9545c40658d67baf057" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1H5V5A003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="false" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%33%30%30f%36%31bc%35%36%36%39c%39%35%34%35c%34%30%36%35%38d%36%37baf%30%35%37%2Fdocument%2FX%31H%35V%35A%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/bcite/X1H5V5A003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/bcite/X1H5V5A003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/bcite/X1H5V5A003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/related_content/X1H5V5A003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1690041647107";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">672 F.3d 372</div>
<div class="cite" data-cite-type="DocketNumber">10-10956</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 42535</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Fifth Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
Christopher Tyler LOFTON, Individually and on behalf of the Estate of
Christopher M. Lofton, deceased; Tegan Nicole Lofton, individually and on
behalf of the Estate of Christopher M. Lofton, deceased; Lauren Lofton,
Plaintiffs-Appellants, v. McNEIL CONSUMER &amp; SPECIALTY
PHARMACEUTICALS, a Division of McNeil-P.P.C. Incorporated; Johnson &amp;
Johnson, Defendants-Appellees.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 10-10956.
</center></p>
<p><center>
February 22, 2012.
</center></p>
<span CLASS="page_no" data-cite="672 f 3d 373" data-cite-type="PrimaryFederalReporter" data-cite-pageno="373" data-primary-citation="672 F.3d 372">[*373]</span> <div id="para2" printdualcolumn="true"><p>
  William F. Zook (argued), Ted B. Lyon &amp; Associates,
Mesquite, TX, for Plaintiffs-Appellants.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Jonathan D. Hacker (argued), Anton Metlitsky, Matthew MacKinnon
Shors, O'Melveny &amp; Myers, L.L.P., Washington, DC, Charles
C. Lifland, O'Melveny &amp; Myers, L.L.P., Los Angeles, CA,
Christy D. Jones, Butler, Snow, O'Mara, Stevens &amp; Cannada,
P.L.L.C., Ridgeland, MS, David Curtis Schulte, Thompson
&amp; Knight, L.L.P., Dallas, TX, for Defendants-Appellees.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Appeal from the United States District Court for the
Northern District of Texas.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before JONES, Chief Judge, and STEWART and SOUTHWICK,
Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  EDITH H. JONES, Chief Judge:
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Christopher M. Lofton tragically died from a rare disease
called Toxic Epidermal Necrolysis ("TEN") after taking Motrin.
Lofton's wife and children brought suit against the Appellees
asserting that Motrin caused the disease and the Appellees had
failed to warn consumers about the risk of these severe
autoimmune allergic reactions. The district court entered
summary judgment for the Appellees. The only issue on appeal is
whether the district court correctly found that federal law
preempts a Texas tort reform law that requires plaintiffs to
assert, in failure to warn cases, that a drug manufacturer
withheld or misrepresented material information to the FDA.
<i>See</i> TEX. CIV. PRAC. &amp; REM. CODE
&sect; <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">82.007</a>(b)(1). We agree with the district court and AFFIRM.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Christopher M. Lofton took over-the-counter Motrin between May
20 and May 22, 2000 to combat a fever. On May 24, after
noticing a rash on his skin, Lofton went to the Piano Medical
Center emergency room, where he reported both the fever and the
rash. After his release, he resumed taking Motrin for pain.
When his skin condition worsened, Lofton saw a dermatologist on
May 26. The dermatologist diagnosed him with Stevens-Johnson
Syndrome ("SJS"), a less advanced form of TEN. The following
day, Lofton returned to the emergency room and was soon
admitted to the burn unit of Parkland Hospital for treatment of
TEN. He died on June 3.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  SJS and TEN are extremely rare maladies, occurring in only
several people per million each year. One known cause of the
diseases is an autoimmune reaction to medication. Whether
ibuprofen is among the medications that can cause TEN is a
contested issue. In a similar case, the Seventh Circuit noted
that "[t]here is un-questionably an <i>association</i>
between SJS/TEN and ibuprofen," but such association might
arise only from patients' use of ibuprofen to combat the
headaches and fevers associated with SJS/TEN. <i>Robinson v.</i>
<i>McNeil Consumer Healthcare</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1E1JFS003?jcsearch=615%20f%203d%20861&amp;summary=yes#jcite">615 F.3d 861</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1E1JFS003?jcsearch=615%20f%203d%20861&amp;summary=yes#jcite">868</a> (7th
Cir. 2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA is aware of the connection between ibuprofen and
SJS/<span CLASS="page_no" data-cite="2012 bl 42535 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[**2]</span> TEN and, starting in February of 2005, required that
ibuprofen labels carry a warning about the symptoms of SJS/TEN.
The warning listed
<span CLASS="page_no" data-cite="672 f 3d 374" data-cite-type="PrimaryFederalReporter" data-cite-pageno="374" data-primary-citation="672 F.3d 372">[*374]</span> 
skin reddening, rash, and blisters among the signs of an
allergic reaction. Also during February 2005, a group that
Appellees describe as "experts retained by plaintiffs in Motrin
litigation," filed a Citizen's Petition with the FDA. The
petition sought additional labeling requirements, including an
express reference to SJS/TEN, and alleged that McNeil and other
manufacturers had withheld information from the FDA regarding
the risk of severe skin disorders. The FDA rejected the
petition, explaining that warnings beyond those already added
would not be useful. Regarding the allegations that McNeil and
other manufacturers withheld information, the agency stated:
"[petitioners] provide no evidence to support this allegation.
In addition, we have no evidence that there is additional
undisclosed safety information that was withheld by the
ibuprofen manufacturers."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Against this background, Lofton's family filed suit asserting
common law negligence and strict products liability claims.
Appellees moved for summary judgment on all claims, asserting
in particular that the failure to warn claims, which are
subject to a "fraud-on-the-FDA" proof requirement under Texas
law, are preempted by <i>Buckman Co. v. Plaintiffs' Legal</i>
<i>Comm.</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. 341</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=148%20l%20ed%202d%20854&amp;summary=yes#jcite">148 L.Ed.2d 854</a>
(2001). The district court delayed ruling on the motion until
the Supreme Court decided <i>Wyeth v. Levine</i>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. 555</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=173%20l%20ed%202d%2051&amp;summary=yes#jcite">173 L.Ed.2d 51</a> (2009), which asked the
Court whether FDA approval of drug labels preempted state
failure to warn claims. Although <i>Levine</i> rejected a
sweeping view of preemption, the district court in this case
nevertheless granted the motion for summary judgment insofar as
it related to the preemption of the Texas provision. <i>Lofton</i>
<i>v. McNeil Consumer &amp; Specialty Pharms.</i>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1CEIGA003?jcsearch=682%20f%20supp%202d%20662&amp;summary=yes#jcite">682 F.Supp.2d 662</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1CEIGA003?jcsearch=682%20f%20supp%202d%20662&amp;summary=yes#jcite">676-78</a> (N.D.Tex. 2010). The Loftons' other claims have been
dismissed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Only one issue survives on appeal. Under Texas law, a drug
manufacturer enjoys a rebuttable presumption that it is not
liable for failure to warn if the FDA has approved "the
warnings or information" accompanying the product alleged to
have harmed the plaintiff. TEX. CIV. PRAC.
&amp; REM. CODE &sect; <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=TEX.%20CIV.%20PRAC.%20%26%20REM.%20CODE%20%2082.007(a)(1)&amp;summary=yes#jcite">82.007</a>(a)(1).<a HREF="#fn100" name="fnref_fn100">[fn1]</a> A plaintiff may rebut the
presumption, <i>inter alia</i>,
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  by establishing that . . . the defendant . . .
  withheld from or misrepresented to the United States
  Food and Drug Administration required information that
  was material and relevant to the performance of the
  product and was causally related to the claimant's
  injury.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=TEX.%20CIV.%20PRAC.%20%26%20REM.%20CODE%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a>. As an affirmative defense, McNeil raised
the &sect; 82.007(a)(1) presumption, and the district court
concluded that the conditions for invoking the provision were
satisfied because McNeil complied with all FDA requirements
governing the
<span CLASS="page_no" data-cite="672 f 3d 375" data-cite-type="PrimaryFederalReporter" data-cite-pageno="375" data-primary-citation="672 F.3d 372">[*375]</span> 
labels of over-the-counter ibuprofen. <i>Lofton</i>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1CEIGA003?jcsearch=682%20f%20supp%202d%20662&amp;summary=yes#jcite">682 F.Supp.2d at 673</a>. The court went on to consider the plaintiffs'
attempt to rebut that presumption based on <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a>.
The court first concluded that "extending the holding of
<i>Buckman</i> to fraud-on-the-FDA exceptions is warranted."
<i></i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1CEIGA003?jcsearch=682%20F.%20Supp.%202d%20662&amp;summary=yes#jcite">Id. at 675</a>. In addition, after noting that the FDA
rejected the 2005 Citizen'<span CLASS="page_no" data-cite="2012 bl 42535 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[**3]</span> s Petition, the court held that
"<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">section 82.007(b)</a>(1) is preempted in some circumstances,
including as here, where Plaintiffs ask the court to reach the
conclusion opposite of that reached by the FDA, that Defendants
did not withhold information or mislead it." <i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1CEIGA003?jcsearch=682%20F.%20Supp.%202d%20662&amp;summary=yes#jcite">Id</a>.</i> As a
result, the district court granted the Appellees' motion for
summary judgement. Ma t 681. This appeal followed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                           STANDARD OF REVIEW
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court reviews a district court's grant of summary judgment
<i>de novo</i> applying the same standard as the district
court. <i>Onoh v. Northwest Airlines, Inc.</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1DSSQA003?jcsearch=613%20f%203d%20596&amp;summary=yes#jcite">613 F.3d 596</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1DSSQA003?jcsearch=613%20f%203d%20596&amp;summary=yes#jcite">599</a> (5th Cir. 2010). The court views all evidence in the light
most favorable to the nonmoving party and grants summary
judgment if there is no genuine issue of material fact and the
movant is entitled to judgment as a matter of law. <i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1DSSQA003?jcsearch=613%20F.3d%20596&amp;summary=yes#jcite">Id</a>.</i>
Questions of law regarding preemption are reviewed <i>de novo.</i>
<i>Tex. Midstream Gas Servs., LLC v. City of Grand Prairie</i>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1DB8U2003?jcsearch=608%20f%203d%20200&amp;summary=yes#jcite">608 F.3d 200</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1DB8U2003?jcsearch=608%20f%203d%20200&amp;summary=yes#jcite">206</a> (5th Cir. 2010).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Provisions similar to <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(a)(1)&amp;summary=yes#jcite">&sect; 82.007(a)(1)</a> and <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">(b)(1)</a> have been
subject to conflicting treatment in the courts of appeals. The
Sixth Circuit held that a Michigan statute similar to the
contested Texas provision is preempted in some applications.
<i>Garcia v. Wyeth-Ayerst Labs.</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XFPLMD?jcsearch=385%20f%203d%20961&amp;summary=yes#jcite">385 F.3d 961</a> (6th
Cir. 2004). The Second Circuit, however, held the same Michigan
statute not preempted. <i>Desiano v. Warner-Lambert</i>
<i>&amp; Co.</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X15OQFC003?jcsearch=467%20f%203d%2085&amp;summary=yes#jcite">467 F.3d 85</a> (2d Cir. 2006), <i>aff'd by an equally</i>
<i>divided court sub nom. Warner-Lambert Co., LLC v. Kent</i>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X18JA02003?jcsearch=552%20us%20440&amp;summary=yes#jcite">552 U.S. 440</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X18JA02003?jcsearch=128%20supreme%20court%201168&amp;summary=yes#jcite">128 S.Ct. 1168</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X18JA02003?jcsearch=170%20l%20ed%202d%2051&amp;summary=yes#jcite">170 L.Ed.2d 51</a> (2008). Both cases
interpreted <i>Buckman</i>, which held that state law
fraud-on-the-FDA claims are preempted because they "conflict
with the FDA's responsibility to police fraud consistently with
the Administration's judgment and objectives."
<i>Buckman</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 350</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1018</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following <i>Buckman</i>, the Supreme Court held that state
common law failure to warn claims are not preempted by FDA
approval of drug labels. <i>Wyeth</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. 555</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>. Consequently, the Loftons' appeal hinges on the
characterization of their case as presenting a failure to warn
claim analogous to <i>Levine</i>, which is not preempted, or
a fraud-on-the-FDA claim analogous to <i>Buckman</i>, which
is. If <i>Buckman</i> is more analogous, we must determine
whether to follow the Second or Sixth Circuit concerning
<i>Buckman'?</i>, applicability to provisions like
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>1.</i> <u>Buckman</u> or <u>Levine</u>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Buckman held that federal law preempts state-law causes of
action claiming that a medical device manufacturer made
fraudulent representations to the FDA. <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 353</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1020</a>. The case involved orthopedic bone screws that
the FDA approved in an expedited process as "substantially
equivalent" to devices already on the market. <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 346</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1016</a>. Plaintiffs who suffered injuries after
implantation of the screws brought suit alleging that the
manufacturer misled the FDA. They further alleged that the
misrepresentations were a "but for" cause of their injuries
because, absent the misrepresentations, the product would never
have reached the market. <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 343</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1015</a>.
<span CLASS="page_no" data-cite="672 f 3d 376" data-cite-type="PrimaryFederalReporter" data-cite-pageno="376" data-primary-citation="672 F.3d 372">[*376]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Court rejected the novel cause of action because the state
law claim would conflict with the FDA's authority to punish
fraud on the agency. The Court stated "that the federal
statutory scheme amply empowers the FDA to punish and deter
fraud against the Administration."<a HREF="#fn200" name="fnref_fn200">[fn2]</a> <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 348</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1017</a>. Not only does <span CLASS="page_no" data-cite="2012 bl 42535 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[**4]</span> federal law provide administrative
tools to punish and deter fraud, but the agency's decision to
employ those tools implicates its discretion and special
competence. Among the factors that make FDA enforcement "a
somewhat delicate balance of statutory objectives,"
<i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20U.S.%20341&amp;summary=yes#jcite">id</a>.</i>, are the need for administrative efficiency and
the possibility that tort liability based on inadequate
disclosures would create "an incentive to submit a deluge of
information," <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 351</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1019</a>. The Court
concluded that authorizing tort liability for failure to comply
with FDA disclosure requirements "would exert an extraneous
pull on the scheme established by Congress, and it is therefore
pre-empted by that scheme." <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 353</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1020</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Levine</i>, the plaintiff brought a traditional failure
to warn claim under state common law for injuries accruing from
the administration of Phenergan. The defendant responded that
because the FDA approved the drug labels, state law claims were
preempted. <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. at 559-60</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. at 1191-92</a>. The Court
rejected the preemption argument as an "overbroad view of an
agency's power to pre-empt state law." <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. at 574</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. at 1199</a>. Among other reasons, the Court noted that the
Food, Drug and Cosmetic Act ("FDCA") contains no express
preemption provision regarding prescription drugs, and federal
law provides no remedy for consumers harmed by unsafe drugs.
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. at 573-74</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. at 1199</a>. The Court was
unpersuaded by the argument for conflict preemption, which
asserted that Wyeth could not simultaneously comply with FDA
labeling regulations and additional requirements imposed by
state common law. <i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=555%20U.S.%20555&amp;summary=yes#jcite">Id</a>. Levine</i> is not the Court's first
holding that state tort actions can complement rather than
conflict with FDA safety regulations. In <i>Medtronic, Inc. v.</i>
<i>Lohr</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">518 U.S. 470</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">495</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X5CCS2?jcsearch=116%20supreme%20court%202240&amp;summary=yes#jcite">116 S.Ct. 2240</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X5CCS2?jcsearch=116%20supreme%20court%202240&amp;summary=yes#jcite">2255</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X5CCS2?jcsearch=135%20l%20ed%202d%20700&amp;summary=yes#jcite">135 L.Ed.2d 700</a> (1996), the Court held that a finding of equivalency by the
FDA, which led to approval of a medical device, did not "den[y]
Florida the right to provide a traditional damages remedy for
violations of common-law duties when those duties parallel
federal requirements." <i>Accord Buckman</i>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 353</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1020</a> "(<i>Medtronic</i> can be read to
allow certain state-law causes of actions that parallel federal
safety requirements.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At first glance, the case at bar bears some resemblance to both
<i>Levine</i> and <i>Buckman.</i> Texas adopted
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007&amp;summary=yes#jcite">&sect; 82.007</a> as a tort reform measure, intentionally restricting
certain common law claims concerning FDA-approved drugs except
where such claims closely parallel the procedures and results
required by the agency itself. Thus, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(a)(1)&amp;summary=yes#jcite">Section 82.007(a)</a>(1)
creates a statutory presumption that drug manufacturers and
related parties are not liable for failure to warn claims if
the FDA approved the label. Under <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a>, the
relevant exception here, the presumption against liability can
be rebutted if the plaintiff can "establish" that the drug
manufacturer "withheld" from the agency or "misrepresented"
"material" information "required" by the FDA. As in
<i>Buckman</i>, the plaintiffs must show fraud-on-the-FDA
<span CLASS="page_no" data-cite="672 f 3d 377" data-cite-type="PrimaryFederalReporter" data-cite-pageno="377" data-primary-citation="672 F.3d 372">[*377]</span> 
for their claims to survive, but as in <i>Le-vine</i>,
the tort covered by the statute is a failure to warn products
liability claim. This hybrid appearance dissolves, however,
when one focuses on <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a>, the contested statutory
provision.
<span CLASS="page_no" data-cite="2012 bl 42535 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[**5]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Buckman's</i> fraud-on-the-FDA analysis is more factually
and legally apposite to the interpretation of
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a>. Moreover, <i>Levine</i> preserves common law
state tort claims that parallel or reinforce the agency's
efforts but do not involve the relationship between the federal
regulator and the regulated entity, the dispositive factor for
federal preemption in <i>Buckman.</i> In fact, neither the
majority nor dissent in <i>Levine</i> cut back on
<i>Buckman</i> or, indeed, found a state law
fraud-on-the-agency theory viable in this broader context. Only
by denying that the Texas statute is what it is &mdash; a
requirement to prove fraud on the FDA &mdash; can
<i>Levine</i> prevail or <i>Buckman</i> be distinguished.
The question then becomes whether to subscribe to the Sixth
Circuit's or Second Circuit's interpretation of
<i>Buckman.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>2. Competing Interpretations of</i> <u>Buckman</u>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As noted above, the courts of appeals split on whether
<i>Buckman</i> requires preemption of a Michigan provision
similar to <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007&amp;summary=yes#jcite">&sect; 82.007</a>.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> In <i>Garcia</i>, the Sixth
Circuit concluded that the Michigan provision is preempted
unless the FDA itself finds that fraud has been committed
during the approval process. <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XFPLMD?jcsearch=385%20f%203d%20961&amp;summary=yes#jcite">385 F.3d at 966</a>. The court
observed that under <i>Buckman</i>, state fraud-on-the-FDA
claims are impliedly preempted by the FDCA because the state
provisions "inevitably conflict with the FDA's responsibility
to police fraud consistently with the Agency's judgment and
objectives." <i></i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XFPLMD?jcsearch=385%20F.3d%20961&amp;summary=yes#jcite">Id. at 965</a> (quoting <i>Buckman</i>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 350</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1018</a>). While the court recognized
that the Michigan provision, which requires evidence of
fraud-on-the-FDA to rebut a presumption of non-liability, is
not a direct fraud-on-the-FDA cause of action, the court did
not find the difference from <i>Buckman</i> significant.
<i></i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XFPLMD?jcsearch=385%20F.3d%20961&amp;summary=yes#jcite">Id. at 965-66</a>. Because the provision ultimately
requires the plaintiff to provide proof that the drug
manufacturer defrauded the FDA, it conflicts with the FDA's
duties and is preempted. <i></i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XFPLMD?jcsearch=385%20F.3d%20961&amp;summary=yes#jcite">Id. at 966</a>. Where the FDA
itself finds fraud, however, the Sixth Circuit would allow the
state claim to proceed because the state tort remedy does not
intrude upon the FDA's responsibility or authority.
<i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XFPLMD?jcsearch=385%20F.3d%20961&amp;summary=yes#jcite">Id</a>.</i>
<span CLASS="page_no" data-cite="672 f 3d 378" data-cite-type="PrimaryFederalReporter" data-cite-pageno="378" data-primary-citation="672 F.3d 372">[*378]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Analyzing the same Michigan statute, the Second Circuit
disagreed with <i>Garcia</i> and distinguished the Michigan
statute from <i>Buckman</i> in three ways. <i>Desiano</i>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X15OQFC003?jcsearch=467%20f%203d%2085&amp;summary=yes#jcite">467 F.3d at 93</a>. First, the traditional "presumption against
preemption" applied to the Michigan statute because it embodies
a state's regulation of health and safety where the presumption
"stands at its strongest." <i></i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X15OQFC003?jcsearch=467%20F.3d%2085&amp;summary=yes#jcite">Id. at 94</a>. The court did
not view the statute as an attempt to police fraud-on-the-FDA
but instead a prerequisite to allowing victims to recover under
existing state product liability laws. <i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X15OQFC003?jcsearch=467%20F.3d%2085&amp;summary=yes#jcite">Id.</a></i> Second, the
underlying claims were traditional product liability claims not
involving a "newly-concocted duty" between the manufacturer and
the federal agency. <i></i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X15OQFC003?jcsearch=467%20F.3d%2085&amp;summary=yes#jcite">Id. at 94</a>-95. Pairing the Michigan
provision with the common law claims distinguished the case
from <i>Buckman</i>, in which the only claim alleged was
fraud-on-the-FDA. <i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X15OQFC003?jcsearch=467%20F.3d%2085&amp;summary=yes#jcite">Id.</a></i> at 95. Moreover, the Second
Circuit posited that the Michigan statute in its entirety
creates an affirmative defense available to drug <span CLASS="page_no" data-cite="2012 bl 42535 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[**6]</span> manufacturers
but does not render fraud-on-the-FDA, asserted on rebuttal by a
plaintiff, an "element" of the plaintiffs claims. Finally, the
court discounted the likelihood that this provision &mdash;
unlike a stand-alone fraud-on-the-FDA claim &mdash; would
engender practical conflict with FDA's approval process and
would inflict a deluge of unnecessary information on the
agency, as the Supreme Court feared in <i>Buckman.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>3.</i> <u>Buckman</u> <i>applied to</i>
<i>TEXAS CIV. PRAC. &amp; REM. CODE &sect; <cite>82.007</cite>(b)(1)</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  a. <i>Presumption Against Preemption</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court has occasionally stated that a preemption
inquiry "start[s] with the assumption that the historic police
powers of the States were not to be superseded by the Federal
Act unless that was the clear and manifest purpose of
Congress." <i>Hillsborough Cnty., Fla. v. Automated Med.</i>
<i>Labs., Inc.</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X5CB42?jcsearch=471%20us%20707&amp;summary=yes#jcite">471 U.S. 707</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X5CB42?jcsearch=471%20us%20707&amp;summary=yes#jcite">715</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X5CB42?jcsearch=105%20supreme%20court%202371&amp;summary=yes#jcite">105 S.Ct. 2371</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X5CB42?jcsearch=105%20supreme%20court%202371&amp;summary=yes#jcite">2376</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X5CB42?jcsearch=85%20l%20ed%202d%20714&amp;summary=yes#jcite">85 L.Ed.2d 714</a> (1985) (internal citations omitted). Among the
traditional police powers, the Court has also occasionally
recognized "the historic primacy of state regulation on matters
of health and safety." <i>Medtronic</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X5CCS2?jcsearch=518%20us%20470&amp;summary=yes#jcite">518 U.S. at 485</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X5CCS2?jcsearch=116%20supreme%20court%202240&amp;summary=yes#jcite">116 S.Ct. at 2250</a>. <i>See also Wyeth</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. at 565</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. at 1194-95</a> (repeating these "presumptions"). <i>But see</i>
<i>Wyeth</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. at 624</a> &amp; n. 14, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. at 1228-29</a>
&amp; n. 14 (Alito, J., dissenting) ("But the <i>Geier [v.</i>
<i>American Honda Motor Co., Inc.</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X2TU0Q?jcsearch=529%20us%20861&amp;summary=yes#jcite">529 U.S. 861</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X2TU0Q?jcsearch=120%20supreme%20court%201913&amp;summary=yes#jcite">120 S.Ct. 1913</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X2TU0Q?jcsearch=146%20l%20ed%202d%20914&amp;summary=yes#jcite">146 L.Ed.2d 914</a> (2000)] Court specifically rejected the
argument . . . that the `presumption against preemption' is
relevant to the conflict-preemption analysis."). Most recently
the Court cast doubt on a presumption against preemption in
<i>PLIVA, Inc. v. Mensing</i>, &mdash; U.S. &mdash;,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1FK52G003?jcsearch=131%20supreme%20court%202567&amp;summary=yes#jcite">131 S.Ct. 2567</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1FK52G003?jcsearch=180%20l%20ed%202d%20580&amp;summary=yes#jcite">180 L.Ed.2d 580</a> (2011). The five-member majority
opinion in <i>PLIVA</i> made no reference to the
"presumption" in the course of upholding implied conflict
preemption over state law claims for failure to maintain
adequate warning labels for FDA-approved generic drugs.
<i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1FK52G003?jcsearch=131%20S.%20Ct.%202567&amp;summary=yes#jcite">Id</a>.</i> Thus, whatever value or relevance a presumption
against preemption of state tort law should play is uncertain.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  What we can conclude with confidence, though, is that the
primacy of the state's police powers is not universal: "the
relationship between a federal agency and the entity it
regulates is inherently federal in character because the
relationship originates from, is governed by, and terminates
according to federal law." <i>Buckman</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 347</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1017</a>. <i>Buckman</i> squarely declined to apply
a presumption against preemption of a state law claim for
fraud-on-the-FDA, as the Court reasoned that federal law
dictates which information the manufacturer is obliged to
disclose and
<span CLASS="page_no" data-cite="672 f 3d 379" data-cite-type="PrimaryFederalReporter" data-cite-pageno="379" data-primary-citation="672 F.3d 372">[*379]</span> 
imposes penalties for omissions and misrepresentations.
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 347-48</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1017</a>. As a result, disclosures
to the FDA are "uniquely federal" and thus beyond the states'
traditional police power. <i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20U.S.%20341&amp;summary=yes#jcite">Id</a>.</i> State laws that depend
on such disclosures are not entitled to a presumption against
preemption. <i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20U.S.%20341&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Writing prior to <i>Levine's</i> or <i>PLIVA's</i>
discussion, or omission, of the "presumption against
preemption," both <i>Garcia</i> and <i>Desiano</i> cited
the presumption, but then diverged in their analyses.
<i>Garcia</i> characterized the Michigan Statute as
preserving claims against drug manufacturers for "circumstances
involving, <i>inter alia</i>, fraud on the FDA."
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XFPLMD?jcsearch=385%20f%203d%20961&amp;summary=yes#jcite">385 F.3d at 965</a>. The court felt bound by <i>Buckman's</i> analysis.
<i></i><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XFPLMD?jcsearch=385%20F.3d%20961&amp;summary=yes#jcite">Id. at 966</a>. <i>Desiano</i>, however, viewed the
Michigan law at a higher level of generality as just another
state-law harmful drug remedy, <span CLASS="page_no" data-cite="2012 bl 42535 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[**7]</span> albeit a remedy limited by proof
of fraud on the FDA "submitted to neutralize a drugmaker's use
of an affirmative defense available under state law."
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X15OQFC003?jcsearch=467%20f%203d%2085&amp;summary=yes#jcite">467 F.3d at 96</a>. The presumption, in other words, might be said to be
tied to the courts' ultimate preemption decision.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Even with the benefit of <i>Levine</i> and <i>PLIVA</i>,
this court is unable to assess the current scope or existence
of the presumption against preemption. We take refuge in the
conclusion that because <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a> requires a Texas
plaintiff to prove fraud-on-the-FDA to recover for failure to
warn, this requirement invokes federal law supremacy according
to <i>Buckman.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>b. <cite>Section 82.007(b)</cite>(1) is a Fraud-on-the-FDA Provision</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007&amp;summary=yes#jcite">Section 82.007</a> is not, like the tort in <i>Levine</i>, an
expression of traditional state common law. The Texas statute
presumptively insulates from liability, for failure to warn,
defendants who made, prescribe, or sell drugs in accord with
FDA standards. TEXAS CIV. PRAC. &amp; REM. CODE
&sect; <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(a)(1)&amp;summary=yes#jcite">82.007</a>(a)(1). <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">Section 82.007(b)</a>(1) eliminates their protection
only in cases where a defendant committed the same fraud that
federal law "amply empowers the FDA to punish and deter."
<i>Buckman</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 348</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1017</a>. Although
the Supreme Court has interpreted the Supremacy Clause to
permit some parallel state law tort suits, the current case
does not raise that issue. State tort claims are impermissible
if they "exist solely by virtue of the FDCA disclosure
requirements." <i>Buckman</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 353</a>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1020</a>. To repeat, the Texas statute requires a plaintiff to
establish that a drug maker "withheld from or misrepresented to
the United States Food and Drug Administration required
information that was material and relevant to the performance
of the product and was causally related to the claimant's
injury." <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a>. The term "required information"
refers to federal requirements under the FDCA; what is
"material" and "relevant" must be determined by FDA itself, not
by state court juries. This language inevitably relies on FDCA
disclosure requirements. Thus, this exception is "premised
principally . . . on a drug maker's failure to comply with
federal disclosure requirements." <i>Desiano</i>,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X15OQFC003?jcsearch=467%20f%203d%2085&amp;summary=yes#jcite">467 F.3d at 95</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Second Circuit attached significance to its
characterization of the underlying claims in <i>Desiano</i>
as traditional tort claims not based on a duty between a
federal agency and drug manufacturer. Likewise, the Loftons'
attempt to distinguish their claim from <i>Buckman</i> as a
traditional failure to warn tort claim. Parenthetically, the
principal question briefed here is not whether a traditional
failure to warn claim is preempted, but whether
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a>, the Texas fraud-on-the-FDA exception to a
presumption, is preempted. But in any
<span CLASS="page_no" data-cite="672 f 3d 380" data-cite-type="PrimaryFederalReporter" data-cite-pageno="380" data-primary-citation="672 F.3d 372">[*380]</span> 
event, <i>Desiano's</i> and Appellants' focus on
"traditional" tort duties is unpersuasive when the statute at
issue conditions recovery on "establishing" what amounts to
fraud on the agency.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Also unpersuasive is the idea that it makes a difference for
preemption purposes whether fraud-on-the-FDA has become an
"element" of traditional tort claims because of the state
statutes, or an item of rebuttal to a defendant's affirmative
defense. We reject the Loftons' specific argument <span CLASS="page_no" data-cite="2012 bl 42535 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[**8]</span> that
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a> "is merely a legislative means to produce some
evidence" of fraud on the FDA to counter the insulation from
liability otherwise afforded by <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(a)(1)&amp;summary=yes#jcite">&sect; 82.007(a)(1)</a>. Either
way, under the Texas provision, a plaintiff must "establish" a
violation of FDA's required disclosures. In so doing, the
plaintiff necessarily retreads the FDA's administrative ground
both to conduct discovery and to persuade a jury. The
Appellants' artful reasoning overlooks the reality of trial
practice and the precise statutory language.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We also disagree with the Second Circuit that statutes like
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a> and the Michigan statute do not pose the
same over-disclosure problems that <i>Buckman</i>
contemplated. The Supreme Court was concerned that "disclosures
to the FDA, although deemed appropriate by the Administration,
will later be judged insufficient in state court."
<i>Buckman</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 351</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1019</a>. When the
FDA has not found fraud, two sorts of interference arise from
these claims. First, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a> allows the state court
to interject varying views on what disclosures are sufficient.
The resulting uncertainty compels manufacturers to flood the
FDA with information to ensure that they retain the
<cite>&sect; 82.007(a)(1)</cite> presumption of non-liability. FDA in turn loses
control over its ability, based on scientific expertise, to
prescribe &mdash; and intelligently limit &mdash; the scope of
disclosures necessary for its work. Second, the statutory
requirement of proving fraud-on-the-FDA may directly invade the
agency's processes when close questions of "withholding" or
"misrepresentation" arise. These dangers are inherent in
<i>Buckman's</i> concern to preserve the agency's discretion
to police the conduct of regulated entities.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While <i>Desiano</i> strains to evoke distinctions between
the claim in <i>Buckman</i> and the Michigan statute, the
Sixth Circuit's approach is more faithful to <i>Buckman.</i>
In cases like this, where the FDA has not found fraud, the
threat of imposing state liability on a drug manufacturer for
defrauding the FDA intrudes on the competency of the FDA and
its relationship with regulated entities. Under such
circumstances <i>Buckman</i> found a violation of the
Supremacy Clause. Thus, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a>, is preempted unless
the FDA itself has found fraud.<a HREF="#fn400" name="fnref_fn400">[fn4]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>4. Severability</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants argue for the first time on appeal that
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a> is not severable from <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(a)&amp;summary=yes#jcite">&sect; 82.007(a)</a>. The
district court, while concluding that federal law preempts
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a>, did not discuss the presumption of adequate
warning in <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(a)&amp;summary=yes#jcite">&sect; 82.007(a)</a>. Appellants concede the severability
argument is newly raised. "[Arguments not raised before the
district court are waived and will not be considered on appeal
unless the party can demonstrate extraordinary circumstances."
<i>French v. Allstate Indem. Co.</i>,
<span CLASS="page_no" data-cite="672 f 3d 381" data-cite-type="PrimaryFederalReporter" data-cite-pageno="381" data-primary-citation="672 F.3d 372">[*381]</span> 
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1F7KR6003?jcsearch=637%20f%203d%20571&amp;summary=yes#jcite">637 F.3d 571</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1F7KR6003?jcsearch=637%20f%203d%20571&amp;summary=yes#jcite">582-83</a> (5th Cir. 2011). The Fifth Circuit has a
"virtually universal practice of refusing to address matters
raised for the first time on appeal." <i>Karl Rove &amp; Co.</i>
<i>v. Thornburgh</i>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X3MRD9?jcsearch=39%20f%203d%201273&amp;summary=yes#jcite">39 F.3d 1273</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X3MRD9?jcsearch=39%20f%203d%201273&amp;summary=yes#jcite">1280</a> (5th Cir. 1994). There
is no reason to deviate from longstanding practice here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because we conclude that <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a> is a
fraud-on-the-FDA provision analogous to the claim considered in
<i>Buckman</i>, we hold <span CLASS="page_no" data-cite="2012 bl 42535 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[**9]</span> that it is preempted by the FDCA
unless the FDA itself finds fraud. The judgment of the district
court is <b>AFFIRMED.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> Unredacted, this section states:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (a) In a products liability action alleging that an
  injury was caused by a failure to provide adequate
  warnings or information with regard to a
  pharmaceutical product, there is a rebuttable
  presumption that the defendant or defendants,
  including a health care provider, manufacturer,
  distributor, and prescriber, are not liable with
  respect to the allegations involving failure to
  provide adequate warnings or information if: (1) the
  warnings or information that accompanied the product
  in its distribution were those approved by the United
  States Food and Drug Administration for a product
  approved under the Federal Food, Drug, and Cosmetic
  Act (<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XEI5LU003?jcsearch=21%20usc%20301&amp;summary=yes#jcite">21 U.S.C. Section 301</a> et seq.), as amended, or
  <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XEI5OG003?jcsearch=21%20U.S.C.%20Section%20351&amp;summary=yes#jcite">Section 351</a>, Public Health Service Act
  (<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XEJ7S6003?jcsearch=42%20usc%20262&amp;summary=yes#jcite">42 U.S.C. Section 262</a>), as amended; or
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (2) the warnings provided were those stated in
  monographs developed by the United States Food and
  Drug Administration for pharmaceutical products that
  may be distributed without an approved new drug
  application.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> The FDA has authority to investigate fraud,
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X19762M003?jcsearch=21%20usc%20372&amp;summary=yes#jcite">21 U.S.C. &sect; 372</a>, consider citizen petitions, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XMAP5Q003?jcsearch=21%20cfr%2010%2030&amp;summary=yes#jcite">21 C.F.R. &sect; 10.30</a>,
and seek criminal and civil penalties particular to
fraud-on-the-FDA, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XEI5ME003?jcsearch=21%20U.S.C.%20%20332&amp;summary=yes#jcite">21 U.S.C. &sect; 332-33</a>. <i>Buckman.</i>
<a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 349</a>, <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X4U3HP?jcsearch=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. at 1017-18</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> Although neither party mentions it, the presumption
accorded defendants under the Michigan law is broader than that
in Texas law. The Michigan presumption covers several products
liability claims if a defendant's product complies with FDA
regulations, while the Texas presumption only applies to
failure to warn claims. The statute reads, in relevant part:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (5) In a product liability action against a
  manufacturer or a seller, a product that is a drug is
  not defective or unreasonably dangerous, and the
  manufacturer or seller is not liable, if the drug was
  approved for safety and efficacy by the United States
  food and drug administration, and the drug and its
  labeling were in compliance with the United States
  food and drug administration's approval at the time
  the drug left the control of the manufacturer or
  seller. . . . This subsection does not apply if the
  defendant at any time before the event that allegedly
  caused the injury does any of the following:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (a) Intentionally withholds from or misrepresents to
  the United States food and drug administration
  information concerning the drug that is required to be
  submitted under the federal food, drug, and cosmetic
  act . . . and the drug would have not been approved,
  or the United States food and drug administration
  would have withdrawn approval for the drug if the
  information were accurately submitted.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
MICH. COMP LAWS &sect; <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XM64AQ003?jcsearch=MICH.%20COMP.%20LAWS%20%20600.2946(5)&amp;summary=yes#jcite">600.2946</a>(5).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> Having decided that <a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/XUUTHG003?jcsearch=Tex.%20Civ.%20Prac.%20%26%20Rem.%20Code%20%2082.007(b)(1)&amp;summary=yes#jcite">&sect; 82.007(b)(1)</a> is preempted, we
need not review the district court's factual determination that
because FDA rejected the 2005 Citizen's Petition, the agency
necessarily found that the Appellees neither withheld
information nor misled it.
</p></div>
</div>
<!--BBLS DD 1690041647107-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1H5V5A003/history">Direct History (2)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1H5V5A003/analysis">Case Analysis (25)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1H5V5A003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
24
</span>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/distinguished.png'>
<div class='citation distinguished icon printHide' title='Distinguished'></div>
<a class='citationAnalysisLabel' href='/bcite/X1H5V5A003/analysis?analysis=distinguished'>
Distinguished
</a>
<span class='citationNumberLabel'>
1
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Medical Devices</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/300f61bc5669c9545c40658d67baf057/document/X1Q6LEDH04O2">10-10956 (5th Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Torts</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/300f61bc5669c9545c40658d67baf057/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "300f61bc5669c9545c40658d67baf057";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY025640&previousPageId=&previousActivityInstanceId=ENTITYf19d29&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:36:37-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1H5V5A003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYf19d29&previousPageId=&previousActivityInstanceId=ENTITY5e2cb5&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:36:34-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1H5V5A003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1H5V5A003";
$('#page_loader').show().spin();
JUDGE_IDS=["15827653","3028300","3028324"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
